Kwaku Marfo

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Alice B. Gottlieb, Atul Deodhar, Iain B. McInnes et al. · Acta Dermato Venereologica · 2022 · 86 citations · Full text

Immunology, Dermatology, Long-term Safety +19

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis

Boni E. Elewski, John W. Baddley, Atul Deodhar et al. · JAMA Dermatology · 2020 · 74 citations · Full text

Lack of Effect in Desensitization With Intravenous Immunoglobulin and Rituximab in Highly Sensitized Patients

Kwaku Marfo, Ming Ling, Yi Bao et al. · Transplantation · 2012 · 73 citations

Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients

Min Ling, Kwaku Marfo, Peter T. Masiakos et al. · Human Immunology · 2012 · 53 citations

Hla, Histocompatibility, Autoimmune Disease +10

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

Mark Lebwohl, Atul Deodhar, C.E.M. Griffiths et al. · British Journal of Dermatology · 2021 · 51 citations